![]() ![]() The most common indication for starting thromboprophylaxis for both 0-21yo and >21yo patients was history of prior VTE, followed by hip replacement. Direct oral anticoagulants (DOACS) were infrequently recommended (3.8% for SCD children and 10.9% for adults) of these, rivaroxaban was used most often. Enoxaparin was the most frequently used anticoagulant among both pediatric and adult practitioners (Figure 2). Nearly all adult practitioners (96.6%) would recommend pharmacologic prophylaxis, mechanical prophylaxis or both for hospitalized adults, but only 76% of pediatric treaters would recommend any prophylaxis (PPX) in hospitalized children (p21yo patients, 51% preferred to use both pharmacologic and non-pharmacologic PPX, 25% preferred pharmacologic alone, with just 5.3% preferring non-pharmacologic PPX only. Of 93 total responses, 14% (N=13) only treat patients >21yo 38.7% (N=36) only treat patients 0-21yo and 47.3% (N=44) treat both. Results: The survey was distributed to approximately 2,550 providers. Chi-square analyses or Fisher’s exact tests for small samples were used to compare proportions as needed. We examined responses to survey questions focused on routine thromboprophylaxis practices in children and adults with SCD prior to the pandemic and in patients with SCD admitted with COVID-19. ![]() Pediatric and adult practitioners were defined as those who medically manage patients 0-21 years of age and >21 years of age respectively. Methods: A cross-sectional electronic survey was distributed to pediatric and adult hematology oncology practitioners through 7 SCD specific interest groups. Thus, VTE management options are often extrapolated from guidelines for the general population. Despite the concern for development of venous thromboembolism (VTE) in these patients, there are no standardized guidelines for routine thromboprophylaxis in either adults or children with SCD. Patients with sickle cell disease (SCD) are predisposed to a hypercoagulable state. Medical practitioners have been prompted to consider prophylactic anticoagulation in special populations diagnosed with COVID-19. Background: The coronavirus disease pandemic of 2019 (COVID-19) has been associated with coagulopathy and an increased rate of thrombosis in adults. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |